2019
Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion
Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, Beitler JJ, Gross N, Jones CU, Kaufman M, Le QT, Semrad TJ, Siu LL, Ridge JA. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. Journal Of Clinical Oncology 2019, 37: jco.19.00441. PMID: 31021656, DOI: 10.1200/jco.19.00441.Peer-Reviewed Original ResearchConceptsProvisional clinical opinionASCO's provisional clinical opinionsTreatment deintensificationOropharyngeal cancerClinical opinionClinical trialsGood prognosis subsetPractice-changing dataTransoral surgical techniquesAmerican Joint CommitteeCancer (AJCC) staging systemEarly-stage diseaseCurrent treatment standardsCurrent treatment approachesCurrent eighth editionLong-term toxicityBetter treatment resultsLate toxicitySystemic treatmentStaging systemIntensity-modulated radiation therapy (IMRT) planningSurgical techniqueTherapeutic decisionsAmeliorate toxicityASCO's membership
2017
Assessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies.
Cmelak A, Flamand Y, Li S, Marur S, Murphy B, Cella D, Forastiere A, Burtness B. Assessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies. Journal Of Clinical Oncology 2017, 35: 6074-6074. DOI: 10.1200/jco.2017.35.15_suppl.6074.Peer-Reviewed Original ResearchFACT-HNQuality of lifeLate toxicityConformal RTLow doseHigh cure ratesRT doseTreatment toxicityCure rateStandard doseVanderbilt HeadNeck cancerKatz IndexPatient outcomesInstrumental activitiesOutcome instrumentsDaily livingDose reductionPRO dataIMRT dosePRO instrumentsRT techniquesFatigue indexDosePatients
2014
E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).
Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). Journal Of Clinical Oncology 2014, 32: lba6006-lba6006. DOI: 10.1200/jco.2014.32.18_suppl.lba6006.Peer-Reviewed Original ResearchClinical complete responseOropharyngeal squamous carcinomaLate grade 3 toxicityPost-treatment neck dissectionStage III/IVAHigh tumor control ratesGrade 3 toxicityWeek x 3Tumor control rateHuman papilloma virusLate toxicityPrimary endpointCurrent smokersComplete responseNeck dissectionNodal stageSquamous carcinomaControl ratePapilloma virusC-IMRTT1-3Weekly schedulePFSInvolved nodesDose